Skip to search formSkip to main contentSkip to account menu

aleglitazar

A dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Aleglitazar binds to both PPARalpha and PPARgamma and… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

OxazolesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
2016
2016
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury
PurposeTo evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against… 
Review
2015
Review
2015
Insulin, Other Hypoglycemic Drugs, and Glucagon
Review
2014
Review
2014
Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review
Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. The associated dyslipidemia adds to… 
2014
2014
The Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of S- and R-Warfarin in Healthy Male Subjects
Abstract: Aleglitazar acts through balanced activation of peroxisome proliferator–activated receptors &agr; and &ggr;; warfarin… 
2013
2013
The dual PPAR-alpha/gamma agonist aleglitazar increases number and function of endothelial progenitor cells: implications for vascular function and atherogenesis
Background: Endothelial progenitor cells (EPC) improve endothelial function and promote vascular repair. Aleglitazar combines… 
2012
2012
No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar
Abstract Aleglitazar is a dual peroxisome proliferator–activated receptor (PPAR)-&agr;/&ggr; agonist in clinical development… 
2012
2012
Abstract 510: Gene Set Enrichment Analysis of the Dual PPAR-α/γ Agonists Aleglitazar and Muraglitazar Reveals Distinct Metabolic Signatures in Human Cardiomyocytes
Dual-acting agonists of the peroxisome proliferator-activated receptors α and γ (PPAR-α/γ) have been pursued to reduce… 
Review
2010
Review
2010
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
  • B. Lecka-Czernik
  • IDrugs : the investigational drugs journal
  • 2010
  • Corpus ID: 31036766
PPARγ and PPARα are nuclear receptors mainly involved in the regulation of glucose homeostasis and lipid levels, respectively… 
2010
2010
Abstract 10854: Aleglitazar, a Balanced Dual PPAR alpha/ gamma Agonist, Decreases Lipolysis and Cytokine Production in a Cellular Model of Inflamed Human Adipose Tissue.
Aleglitazar is a balanced dual peroxisome proliferator-activated receptor (PPAR) alpha/ gamma agonist, designed to optimize lipid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)